Article

Medicare Recipients Save $4.5 Billion on Prescriptions

Medicare beneficiaries have saved a total of about $4.5 billion on prescription medications because of the 2010 health care law since January 2011, the Department of Health and Human Services plans to announce today.

"We're seeing consistent, steady savings for seniors thanks to the health care law," said Jon Blum, director of the Center for Medicare. "In just 21/2 half years, seniors have seen billions in savings, and those savings will continue to grow as the doughnut hole is fully closed."

Read the full story: http://usat.ly/TaRdL3

Source: USA Today

Related Videos
Emma Achola-Kothari, PhD
Dr Emma Achola-Kothani
Dr Emma Achola-Kothari
John Barkett, MBA
CK Wang, MD, COTA
John Barkett, MBA
Tom Belmont
Pieter Sonneveld, MD, PhD
Related Content
Adolescent patients were more likely to be most bothered by feelings of anxiety or atopic dermatitis affecting their daily activities. | Image Credit: InfiniteStudio - stock.adobe.com
May 22nd 2025

Patient-Reported Experiences Show Psychological Impact of Atopic Dermatitis on Adolescents

AJMC Contributor
The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.
managed care cast logo
April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD
On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Even among patients with MDS and anemia with a high transfusion burden, 7 of 12 patients who responded experienced responses lasting longer than 6 months. | Image Credit: Eleni - stock.adobe.com
May 22nd 2025

Safety, Efficacy of Luspatercept for MDS Confirmed in Real-World Setting

Rose McNulty
Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Pill bottle with money inside | Image credit: Kenishirotie - stock.adobe.com
May 20th 2025

HHS Sets Pricing Target for Trump’s Most Favored Nation Drug Price Model

Laura Joszt, MA
Following President Donald Trump's most favored nation executive order, HHS and CMS have released the target price for pharmaceutical manufacturers to meet.
Data from this new study show that cutoffs as low as 2% were associated with poor outcomes in IPF, even when accounting for other known prognostic factors. | Image Credit: Crystal light - stock.adobe.com
May 20th 2025

Real-World Findings Suggest New Look at Thresholds for IPF Progression

AJMC Contributor
Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo